Tim Krzeminski, Healthcare Compliance Director, PwC
Ryan Hayden, Partner, PricewaterhouseCoopers
- Utilizing data analytics to monitor the 340B Drug Discount Program allows healthcare systems to ensure compliance with the 340B Program and maximizes cost-saving opportunities afforded by the 340B Program
- KPIs allow for granular analysis of high risk area related to diversion, duplicate discounts, the GPO prohibition, and provide insights into missed cost- saving opportunities where split-billing software limitations and/or poor master data come into play
- Reduce risk of fines and sanctions by regulators and protection against reputational damage; Improve risk management from automated continuous monitoring for 100% of transactions; Reduce number of FTEs used to maintain compliance with 340B program
Presentation & handouts
DOWNLOAD MP4 FILE
To save the video to your computer right-click the link above then choose SAVE TARGET AS (or SAVE LINK AS) then save the file.